Ovarian Suppression Plus Letrozole Plus Everolimus for Hormone Receptor-Positive, Tamoxifen and Ovarian Suppression Pretreated, Premenopausal Women With Recurrent or Metastatic Breast Cancer[LEO]
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Everolimus (Primary) ; Letrozole; Leuprorelin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms LEO
- 24 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2018.
- 24 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.
- 30 Jan 2015 New trial record